CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleRevenue is $13.44M, lower than 95% of all stocks globally
- PositionOperating margin is -120.7%, lower than 95% of its Medical Devices peers (median 8.1%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.71BHKD472.81M · vs all stocks (USD)
Revenue (TTM)
105.40MCNY13.44M · vs all stocks (USD)
Profit Margin
-299.41%vs Medical Devices peers
Beta
0.6440xvs all stocks
52-Week Change
-13.29%vs all stocks
Market Capitalization
3.71BHKD472.81M · vs all stocks (USD)
Enterprise Value
3.03BHKD386.82M · vs all stocks (USD)
Price to Sales (TTM)
34.52xvs Medical Devices peers
Price to Book (MRQ)
3.40xvs Medical Devices peers
Enterprise to Revenue
28.79xvs Medical Devices peers
Enterprise to EBITDA
-11.83xvs Medical Devices peers
Profit Margin
-299.41%vs Medical Devices peers
Operating Margin
-120.74%vs Medical Devices peers
Return on Assets (TTM)
-15.04%vs Medical Devices peers
Return on Equity (TTM)
-32.27%vs Medical Devices peers
Revenue (TTM)
105.40MCNY13.44M · vs all stocks (USD)
Revenue per Share (TTM)
0.2130CNYUpdated Aug 20, 2026Gross Profit (TTM)
96.00MCNY12.24M · vs all stocks (USD)
EBITDA (TTM)
-256.45MCNY-32.69M · vs all stocks (USD)
Net Income (TTM)
-315.57MCNY-40.23M · vs all stocks (USD)
Operating Cash Flow (TTM)
-87.26MCNY-11.13M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-30.53MCNY-3.89M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Minority Interest (Equity)
-16.28MCNYFY2025 · Dec 31, 2025Revenue
90.59MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
8.07MCNYFY2025 · Dec 31, 2025Gross Profit
82.52MCNYFY2025 · Dec 31, 2025Operating Income
-229.42MCNY-34.12M · vs all stocks (USD)
Pre-tax Income
-272.70MCNYFY2025 · Dec 31, 2025Income Tax Expense
0.00CNYFY2025 · Dec 31, 2025Net Income
-272.70MCNYFY2025 · Dec 31, 2025EBIT
-271.84MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-252.08MCNYFY2025 · Dec 31, 2025Research & Development
183.61MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
53.41MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
13.82MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
867.00KCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
-272.70MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
1.48MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-190.09MCNYFY2025 · Dec 31, 2025Free Cash Flow
-193.33MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
507.40MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-272.70MCNYFY2025 · Dec 31, 2025Stock-based Compensation
96.85MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-12.95MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-8.81MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
7.53MCNYFY2025 · Dec 31, 2025Capital Expenditures
-3.24MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.83MCNYFY2025 · Dec 31, 2025Purchase of Investments
-340.13MCNYFY2025 · Dec 31, 2025Sale of Investments
351.88MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
8.51MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00CNYFY2025 · Dec 31, 2025Long-term Debt Payments
-16.66MCNYFY2025 · Dec 31, 2025Common Stock Repurchase
-360.00KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-17.02MCNYFY2025 · Dec 31, 2025Shares Outstanding
417.17MSharesUpdated Aug 20, 2026Float Shares
182.08MSharesUpdated Aug 20, 2026% Held by Insiders
46.82%vs all stocks
% Held by Institutions
10.32%vs all stocks
Total Cash (MRQ)
629.53MCNY80.26M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.30CNYUpdated Aug 20, 2026Total Debt (MRQ)
55.10MCNY7.02M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0613xvs Medical Devices peers
Current Ratio (MRQ)
5.86xvs Medical Devices peers
Book Value per Share (MRQ)
2.20CNYUpdated Aug 20, 2026Total Assets
896.23MCNY133.28M · vs all stocks (USD)
Total Current Assets
620.61MCNYFY2025 · Dec 31, 2025Total Liabilities
123.11MCNYFY2025 · Dec 31, 2025Total Non-current Assets
275.62MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
17.23MCNYFY2025 · Dec 31, 2025Total Current Liabilities
105.87MCNYFY2025 · Dec 31, 2025Cash
507.36MCNYFY2025 · Dec 31, 2025Cash Equivalents
41.00KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
507.40MCNYFY2025 · Dec 31, 2025Other Short-term Investments
20.00MCNYFY2025 · Dec 31, 2025Accounts Receivable
6.84MCNYFY2025 · Dec 31, 2025Inventory
27.11MCNYFY2025 · Dec 31, 2025Accounts Payable
25.15MCNYFY2025 · Dec 31, 2025Short-term Debt
30.13MCNYFY2025 · Dec 31, 2025Long-term Debt
17.23MCNYFY2025 · Dec 31, 2025Common Stock (Book)
417.17MCNYFY2025 · Dec 31, 2025Retained Earnings
-1.75BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
773.13MCNY114.97M · vs all stocks (USD)
Treasury Stock
360.00KCNYFY2025 · Dec 31, 202552-Week Low
6.00HKDUpdated Aug 20, 202652-Week High
11.98HKDUpdated Aug 20, 202652-Week Change
-13.29%vs all stocks
Beta
0.6440xvs all stocks
50-Day MA
7.35HKDUpdated Aug 20, 2026200-Day MA
8.51HKDUpdated Aug 20, 2026Avg 10-Day Volume
17.94KSharesUpdated Aug 20, 2026Avg 30-Day Volume
213.69KSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-0.7400CNYUpdated Aug 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -120.7%, lower than 95% of its Medical Devices peers (median 8.1%)Significant
Operating margin: -1.21Industry median: 0.08Industry P5: -0.73Peers compared: 102
Profit margin is -299.4%, lower than 95% of its Medical Devices peers (median 4.8%)Significant
Profit margin: -2.99Industry median: 0.05Industry P5: -1.45Peers compared: 102
Financial Health
Altman Z-Score 12.54: safe zoneNotable
Altman Z-Score: 12.54
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Revenue is $13.44M, lower than 95% of all stocks globallySignificant
Revenue (USD): 13,436,841.187Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Anhui Sunhere Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Onconic Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Orthofix Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangsu Hanbon Science & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tuoxin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Leadman Biochemistry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yungshin Global Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chison Medical Technologies Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Kawin Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cabaletta Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Jiangsu Hengli Hydraulic Co., Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Halo Microelectronics Co., Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets